CD274 and neoplasm: A positive response to checkpoint inhibitor therapy has been associated with a high expression of PD-L1/CD274 on tumor-infiltrating immune cells indicating a role for PD-L1/CD274-expressing immune cells in suppressing antitumor responses, which are reinvigorated on checkpoint blockade therapy [15].